Date:2/26/2013

r>73,857Cost of products sold22,44117,80369,83962,053Gross profit5,0093,77115,47911,804Operating expenses4,0543,99012,20511,950Operating earnings (loss)955(219)3,274(146)Other income84193260228Interest expense(80)(110)(295)(333)Earnings (loss) before income taxes959(136)3,239(251)Income tax expense (benefit)177(170)962(237)Net earnings (loss)782342,277(14)Less: net earnings attributable tothe noncontrolling interest238156450211Net earnings (loss) attributable to Kewaunee Scientific Corporation$
544$
(122)$
,827$
(225)Net earnings (loss) per share attributable toKewaunee Scientific Corporation stockholdersBasic$
.21$
(0.05)$
.71$
(0.09)Diluted$
.21$
(0.05)$
.71$
(0.09)Weighted average number of common  shares outstandingBasic2,5902,5792,5862,579Diluted2,6042,5792,5962,579 Kewaunee Scientific CorporationCondensed Consolidated Balance Sheets(in thousands)January 31,April 30,20132012Assets(Unaudited)Cash and cash equivalents$
4,202$
,188Restricted Cash692704Receivables, less allowances20,06423,244Inventories12,88811,760Prepaid expenses and other current assets2,2691,702Total Current Assets40,11543,598Net property, plant and equipment14,89015,346Other assets5,6185,192Total Assets$
,623$
4,136Liabilities and EquityShort-term borrowings$
2,707$
,816Current obligations under capital leases and long-term debt200236Accounts payable8,5628,848Other current liabilities4,3604,340Total Current Liabilities15,82920,240Other non-current liabilities12,09512,238Total Liabilities27,92432,478Noncontrolling interest1,8452,147Kewaunee Scientific Corporation equity30,85429,511Total Equity32,69931,658Total Liabilities and Equity$
,623$
4,136 

Contact:

D. Michael Parker704/871-3290 

'/>"/>

SOURCE Kewaunee Scientific Corporation Copyright©2012 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine technology :

1. Kewaunee Scientific Reports Significantly Improved Results for Fourth Quarter
2. Kewaunee Scientific Corporation Declares Quarterly Dividend
3. Kewaunee Scientific Reports Record Sales for Second Quarter
4. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
5. Shire to Present Scientific Data Across Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting May 5-9
6. Boston Scientific and Philips Healthcare Announce Collaboration to Enhance Imaging Equipment Offering
7. Boston Scientific Announces Positive Data From Lotus™ Transcatheter Aortic Valve Trial
8. One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY™ Stent Versus PROMUS Element™ Platinum Chromium Stent
9. Generex Announces New Members of Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine
10. Boston Scientific Announces FDA Approval and U.S. Launch of EPIC™ Vascular Stent
11. Generex Augments Antigen Express Scientific Advisory Board